Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products

Jesse Elias,1 Pamela M Ling1,2

ABSTRACT

Background Tobacco companies are introducing new ‘heat-not-burn’ cigarettes in dozens of countries. Historically, these products failed commercially, and independent researchers contested their health claims. The most prominent early heat-not-burn cigarette was RJ Reynolds’s (RJR’s) Premier, introduced in the USA in 1988. Curiously, The Lancet endorsed Premier as a ‘near-perfect low tar cigarette’ in a 1991 editorial, 2 years after Premier had been removed from the market. We examined the context of this endorsement.

Methods To ascertain what RJR knew about this endorsement, we systematically searched and analysed previously secret RJR documents in public archives and triangulated the industry document data with other published work.

Results RJR had a long-standing interest in collaborating with outside scientists to endorse potentially reduced harm cigarettes. The author of The Lancet editorial had previously corresponded with RJR regarding Premier’s health effects and market potential. Internally, RJR regarded The Lancet’s editorial, its stance on novel tobacco products, and its endorsement of Premier as major successes. While the editorial came too late to save Premier, RJR saw future business opportunities for novel products if endorsed by health authorities.

Conclusions Endorsement by high-impact medical journals and health authorities may be critical in helping heat-not-burn’ products succeed where previous attempts have failed. Conflicts of interest influenced these endorsements in the past. Health leaders and academic journals should consider both conflicts of interest and the ethics of endorsing tobacco product substitution, as tobacco companies simultaneously work to promote cigarette smoking and undermine tobacco control globally.

BACKGROUND

Since the 1960s, the tobacco industry has developed ‘safer’ products to attract health-conscious smokers and improve its public image.1 Major tobacco companies have recently expanded their product portfolios to include alternative nicotine products, such as electronic cigarettes (e-cigarettes) and ‘heat-not-burn’ cigarettes.2 In 2015, Philip Morris International (PMI), British American Tobacco (BAT), RJ Reynolds (RJR; now owned by BAT) and Japan Tobacco International (JTI) all launched heat-not-burn products in dozens of countries. Heat-not-burn cigarettes have a near 30-year record of dismal market performance.3 4 RJR introduced the first heat-not-burn product—Premier ‘smokeless’ cigarettes—in the USA in 1988. RJR internally hoped Premier would ‘address the growing pressures cigarette smokers face on the subjects of smoking and health, environmental tobacco smoke, and other issues related to the social acceptability of smoking.’5 In an internal memo to employees, RJR’s President of Development Richard Kempe described Premier as ‘one of the most important projects any of us will be involved in during our professional lives…because the success of this project could easily result in a tremendous long-term competitive advantage to RJR and would clearly have a substantial impact on the industry as we know it.’6 Smokers nonetheless widely rejected the product’s taste, smell and difficulty of use. Having invested $300 million ($633 million inflation-adjusted to 2018), RJR removed Premier from test markets after only 6 months.

In 1991, 2 years after Premier’s failure, The Lancet published an editorial praising Premier’s ability to deliver nicotine with fewer carcinogens.7 The editorial, called for health authorities, particularly in the UK, to promote cigarettes that delivered nicotine with as little accompanying tar as possible. As one of the earliest examples of an influential journal promoting a novel tobacco product, The Lancet’s endorsement of Premier provides important context for the tobacco industry’s current pursuit of health authority endorsements for its new products.8

Though the 1991 editorial appeared after Premier’s demise, RJR viewed The Lancet’s position as promising evidence that some health authorities would support novel tobacco products, and that with such endorsements, consumers might accept future products.

METHODS

We analysed previously secret internal tobacco industry documents available through the Truth Tobacco Industry Document Library (https://industrydocuments.library.ucsf.edu/tobacco/) between January 2016 and February 2017. In seeking to identify why The Lancet endorsed Premier in 1991, we combined qualitative analytical methods with iterative search strategies.9 11 Initial keyword searches included: ‘Lancet’ AND ‘Premier’; ‘Nicotine use after the year 2000’; ‘editorial’ AND ‘Premier’ and ‘Chemical and Biological Studies of a Cigarette that Heats Rather than Burns Tobacco’. On learning that two historians attributed the anonymous editorial to Michael Russell,2 12 we conducted further searches with keywords including: ‘Michael Russell’, ‘MAH Russell’ AND ‘Premier’. We conducted snowball searches to locate related documents using reference (Bates) numbers, file locations, dates and individuals mentioned in pertinent documents. Triangulation with online search engines and
news coverage (eg, Google News) generated data that helped resolve and contextualise questions raised by the documents. We repeated iterative searches until keywords and documents yielded only previously viewed documents, suggesting saturation. This analysis is based on a final set of 196 documents.

**RESULTS**

In a 1988 internal memo, RJR insisted that in its marketing of Premier, the company was:

>[Not claim[ing] that the cigarette is ‘safe’ or ‘safer’... [instead] we have used the word ‘cleaner’... This is not a therapeutic claim... Premier’s tobacco-heating technology is a breakthrough that ‘changes the very composition of the smoke – substantially reducing many of the controversial compounds found in smoke of tobacco-burning cigarettes.]

RJR President and CEO for West Germany, Peter Fischer, stressed that, when meeting with policy makers, RJR’s scientific representatives should ‘concentrate on “tar”?condensate related scientific aspects of [Premier] thereby avoiding to address [sic] the remaining nicotine and CO issues’14 which, if independently interrogated, might lead scientists to refute Premier’s implicit health claims as ‘cleaner’.

Legally restricted from making health claims, RJR depended on the scientific community and media to make those claims on its behalf. Proctor notes that Premier’s marketing campaign included ‘one-on-one briefings with university presidents, medical school deans, science writers, and medical organizations, along with politicians and “opinion leaders” throughout the world’.15 In a confidential 1987 planning document, Fischer discussed strategy to ‘insure [sic] a successful product launch’ for Premier, recommending RJR ‘build strong support for the product concept among scientific, regulatory and political constituencies’.14

In 1990, to garner scientific and public support for Premier, Donald deBethizy, a senior toxicologist and Vice President of Research and Development at RJR, published a paper with nine other RJR scientists that compared the nicotine absorption, urine mutagenicity and carcinogens in mainstream smoke from Premier to a conventional cigarette.15 According to the paper—entitled “Chemical and Biological Studies of a Cigarette that Heats Rather than Burns Tobacco”—all chemical and carcinogen levels, save formaldehyde, were lower among Premier smokers.16 The authors attributed these reductions to Premier’s smoke, reported as consisting of more than 90% water, glycerol and propylene glycol.15

**The Lancet endorses Premier**

Before its publication in the *Journal of Clinical Pharmacology*, deBethizy’s paper was rejected by the *Journal of the American Medical Association*17 and the *New England Journal of Medicine*.18 In October 1989, deBethizy submitted the paper to *The Lancet*, hoping for ‘better luck in England’,19 despite the product already having been pulled from US shelves 8 months earlier.20 The *Lancet* also rejected the paper on the grounds that its printing in the journal was ‘not justifiable’.21 In the rejection letter, *The Lancet* editor David Sharp nonetheless called the paper ‘a substantial study... [that] deserves to be published in full’,21 Sharp proposed a future editorial about Premier should a different journal publish the article.21 Over a year later, deBethizy notified *The Lancet* of the paper’s publication in the *Journal of Clinical Pharmacology* and requested the editorial.16

In this follow-up letter, deBethizy argued that Premier ‘speak[s] directly to the call by the Frogett (sic) Committee in Great Britain for reduced “tar” to nicotine ratio cigarettes’16 The Froggatt Committee was, since Peter Froggatt’s appointment as chair, the informal name of the Independent Scientific Committee on Smoking and Health (ISCSH; earlier known as the Hunter Committee). The ISCSH served as the UK government’s chief scientific advisory body on the issue of smoking and health through the 1970s and 1980s and was openly advised by major British tobacco manufacturers.22 Effectively, deBethizy, an RJR scientist, used the authority of the ISCSH, which was under industry influence, to stress to *The Lancet* the importance of RJR-funded findings on Premier (an RJR product). In his letter, deBethizy set Premier in a framework promoting tobacco product substitution:

The public health community in the US has not been receptive to these prototypes, taking the position that prohibition of smoking is the only avenue that should be pursued. We believe that this is a short-sighted approach which ignores the projections that by the year 2000, forty million Americans and an even greater number worldwide will choose to smoke... We feel that cigarettes that heat tobacco will provide an alternative to smokers who choose to smoke despite warnings that adverse health effects may arise from smoking.16

While we found no return correspondence from *The Lancet*, the journal published the editorial 6 months later.21 Historians Virginia Berridge and Mark Elam2 12 attribute this editorial’s authorship to Michael Russell, one of Britain’s most prominent tobacco scientists during the second half of the 20th century. We found no evidence of collaboration between RJR and Michael Russell regarding the content of this editorial.

**Michael Russell**

Michael Russell is oft-quoted as stating, ‘people smoke for nicotine but they die from the tar’.23 A psychiatrist by training, Russell is today widely regarded24 25 as influential in British health organisations26–28 and authorities29 30 promotion of e-cigarettes for long-term nicotine maintenance and cessation purposes. One of the first researchers to identify nicotine as the primary reason for which smokers became addicted, Russell was an early developer of and advocate for nicotine replacement therapy.31 Among other proposals, Russell promoted medium and high nicotine, low tar cigarettes so as to avoid smokers’ ‘compensation’, a phenomenon in which low-tar cigarette smokers inhale more deeply to obtain nicotine, thereby ingesting as much, if not more tar and negating any ‘health’ benefits of low-tar cigarettes.23

In the late 1970s, Russell collaborated with BAT on two ‘safer’ cigarette studies12 and received £55,000 (£300,850 inflation adjusted to 2018) in funding to conduct a third joint study, testing medium nicotine, low tar cigarettes.33–36 38 Russell acknowledged this ‘strong relationship with BAT’ and their ‘help with some funding’ in a 2004 interview with Addiction, commenting that maintaining relationships with tobacco companies was common practice among researchers at the time.37 Russell also engaged extensively with RJR about Premier’s ‘positive aspects’,38 both prior to the product’s release and following its failure (box 1).

In August 1988, Russell requested 3000 Premier cigarettes from RJR to conduct a study measuring ‘nicotine, cotinine and carboxyhemoglobin levels in persons smoking Premier’.39 On RJR’s approval of his study in October 1988, Russell stated that the ‘publication of results in an English Medical Journal’, showing Premier to have fewer carcinogens than regular cigarettes, ‘could go a long way to raising interest here [i.e. in the UK] and casting a favorable light on things’.40 The first time RJR attempted to send Premier cigarettes to Russell, however, British customs detained
August 1988: Michael Russell writes to RJ Reynolds (RJR) requesting 3000 Premier cigarettes for 'a week-long study with 10–12 male smokers... [to] monitor plasma, nicotine, cotinine and carboxyhemoglobin levels in persons smoking Premier'. Jack Blanchard, Director of Scientific Relations at RJ Reynolds, saw this correspondence as a 'result of discussions that Dr. Russell had with several of us on this topic... last month'. Blanchard suggests to Wallace Hayes, Vice President of Research at RJR, that research scientist Donald J. deBethizy interact with Russell to facilitate these studies.

August 1988: Michael Russell writes to RJ Reynolds (RJR) requesting 3000 Premier cigarettes for 'a week-long study with 10–12 male smokers... [to] monitor plasma, nicotine, cotinine and carboxyhemoglobin levels in persons smoking Premier'. Jack Blanchard, Director of Scientific Relations at RJ Reynolds, saw this correspondence as a 'result of discussions that Dr. Russell had with several of us on this topic... last month'. Blanchard suggests to Wallace Hayes, Vice President of Research at RJR, that research scientist Donald J. deBethizy interact with Russell to facilitate these studies.

September 1988: RJR reacts to this request by sending a copy of the paper and recent articles on Premier to Michael Russell, whom he thanks in a letter for his interest in writing an editorial about Premier. Russell also advised RJR in correspondence to seek advice from prominent physicians to propose tobacco product modification as an essential component to a realistic public health policy on smoking and health.

November 1988: Premier introduced to American test markets.

February 1989: Premier withdrawn from American test markets. Russell also mentioned having done a 'preliminary study with [Premier] cigarettes that we purchased ourselves'. This preliminary study may have been the basis for a 1993 paper that Russell coauthored in Thorax, showing lower average nicotine, carbon monoxide and tar intake among Premier smokers.

Four months after this January 1991 correspondence, the anonymous editorial, 'Nicotine Use After the Year 2000', appeared in The Lancet, praising Premier as a 'near-perfect low tar cigarette'.

In the tradition of newspapers, The Lancet publishes unsigned editorials, occasionally from outside authors whose opinion reflects the journal’s editorial board and represents the position of The Lancet. Russell’s editorial urged the British government to promote the long-term, recreational and even addictive use of nicotine as a cessation therapy provided the nicotine could be delivered alongside as little tar as consumers found acceptable.

Russell also proposed a future editorial on Premier should the article be published elsewhere.

January 1990: deBethizy submits paper to Journal of Clinical Pharmacology, on recommendation by Eliot Vessel.

August 1990: deBethizy paper published in Journal of Clinical Pharmacology.

December 1990: deBethizy alerts The Lancet to the article’s publication, hoping the journal will follow up on its initial interest in writing an editorial about Premier.

January 1991: Russell writes to RJR proposing future tests on Premier that he could lead were funding from RJR granted.

May 1991: Editorial praising Premier (attributed to Russell) appears in The Lancet.
as a major business opportunity. In September 1991, deBethizy and one of his coauthors, David Doolittle, cited The Lancet’s endorsement of Premier in a letter to RJR President James Johnston. deBethizy and Doolittle advocated that the company should continue to market products that specifically respond to consumers’ increasing ‘health consciousness,’ in order to ‘stabilize[e] or reverse[ ] market decline’.57 As health concerns around smoking intensified, the two scientists argued that the ‘long-term vitality’ of RJR would depend on repositioning cigarettes to address these concerns. The letter stated, ‘one can only imagine the market share’ that such products, ‘uniquely perceived...as less hazardous,’ stood to secure.47

RJR executives again acknowledged the importance of third-party endorsements after Premier was removed from the market. In 1993, Russell wrote to Carl Ehmann, RJR’s Research Director, arguing that RJR should not abandon Premier or similar potentially reduced harm products.49 Ehmann responded that RJR was confident it could redress Premier’s shortcomings and introduce a similar product that smokers would accept.50 Nonetheless, Ehmann stated that the company’s ability to market such a product [in the future] will be dependent upon more rational scientists, like yourself, speaking up and encouraging such concepts. Otherwise, we will be at the mercy of anti-smoking zealots who mistakenly believe they can engineer a smoke-free society and therefore have no interest in products which address the very issues about which they are concerned.49

DISCUSSION

A major UK medical journal’s endorsement of a defunct American tobacco product was aided by an enthusiastic scientist’s cooperation with RJR tobacco company. This scientist’s conflict of interest with the maker of Premier should have been, at the very least, disclosed by both Russell and The Lancet. Russell’s conduct (eg, soliciting funding from RJR and stating a priori that publication of the study results in an English journal could go a long way to ‘casting a favorable light on things’;40 offering to ‘lose’ records of reimbursement from RJR,40 and suggesting RJR pay him to undertake research on a product he later anonymously endorsed while representing The Lancet45) raises serious questions of integrity. It is unclear whether these conflicts of interest were disclosed to the journal, or why the journal offered to write the editorial for a paper they deemed ‘not justifiable’ for publication in The Lancet. Current industry communications attribute new products’ public health impact to consumer acceptance,50 framed publicly more simplistically than their internal research,51 as the product of nicotine, taste and the user’s associated ‘ritual’.52 Our analysis, however, suggests that health-authority backing will also be central in determining whether the next generation of heat-not-burn devices succeeds where previous attempts have failed.

The industry document database consists mainly of documents produced during litigation and is not a complete archive. As such, we may have missed relevant information, particularly information contained in documents that the industry has withheld on the grounds of trade secrets or client/lawyer privilege.53 Nonetheless, the documents we have analysed provide a window into prominent RJR scientists’ and executives’ candid discussions of a potentially reduced harm product. These insights may help public health professionals craft policy that anticipates reiterations of the tobacco industry’s promotional strategies for its newest crop of products.

While Premier was a commercial failure, the industry has continued to pursue potentially reduced risk tobacco products.54 The major tobacco companies have adopted ‘harm reduction’ language to promote their product portfolios.55 In 2014, PMI introduced its heat-not-burn product IQOS in Italy and Japan, before expanding to 30 other markets within 2 years. In 2015, BAT and JTI launched heat-not-burn products in Japan. In December 2016, PMI filed an application to the Food and Drug Administration so that it may market IQOS as a modified risk tobacco product in the USA.56 PMI now claims that its ‘vision...is that these [reduced-harm] products will one day replace cigarettes’,57 and in September 2017 announced it would commit $1 billion to the establishment of the ‘Foundation for a Smoke-Free World’.58 Wells Fargo analyst Bonnie Herzog has predicted that heat-not-burn products could displace ‘up to 30 percent of the combustible cigarette industry in developed markets by 2025’,59 although sales for IQOS, the current industry leader, began to plateau in the first quarter of 2018.60

The industry has also continued courting public health endorsement of its new products. PMI’s ‘Foundation for a Smoke-Free World’ claims to want to combat cigarette smoking via public health partnerships and the promotion of new products.58 Part of the Foundation’s launch included publication of an article in The Lancet,63 penned by Derek Yach, a former WHO official who previously worked in tobacco control. While many oppose the Foundation,61 and The Lancet also published a comment by public health advocates voicing concerns,62 The Lancet editorial board failed to support the WHO’s strong stance against industry cooperation in their accompanying editorial.63

Nearly 1000 peer-reviewed papers based on tobacco industry documents, as well as the US District Court’s ruling that the tobacco companies violated the Racketeer Influenced Corrupt Organizations Act64 demonstrate the folly of partnership with the tobacco industry. August public health organisations, authorities and journals that believe ‘the best science must lead to better lives’65 should consider the ethics of endorsing tobacco industry

What this paper adds

What is already known on this subject

► The tobacco industry has long viewed the endorsement of external authorities as necessary to the success of its potentially reduced harm products.

► In 1991, The Lancet endorsed RJ Reynolds’ (RJR) heat-not-burn cigarette, Premier, as a safer alternative to traditional cigarettes.

► While Premier failed commercially, the support of potentially reduced harm tobacco products as substitutes continues among some public health organisations and authorities, and is aggressively promoted by tobacco and electronic cigarette manufacturers.

What this paper adds

► The author of The Lancet’s editorial had previously collaborated with and advised RJR on Premier.

► While the editorial appeared after Premier was removed from the market, RJR internally regarded The Lancet’s stance on Premier as both opening a critical business opportunity for harm-reduced products and as an important departure from health authorities in the USA.

► Endorsements by respected health leaders are likely to play a critical role in determining new heat-not-burn tobacco products’ commercial fate and may help the newest crop of modified tobacco products succeed where previous attempts have failed.
attempts to preserve profits with products claimed to be, but not yet demonstrated as reduced risk, while simultaneously continuing to both aggressively promote cigarettes and undermine tobacco control worldwide. Public health practitioners should also bear in mind past experience with industry-backed ‘safer’ cigarettes (eg, filtered and low-tar) that served to undermine and delay tobacco control efforts. Endorsements from health leaders and regulatory authorities may be the key factor in determining current heat-not-burn products’ commercial success, as well as the tobacco industry’s future legitimacy as it promotes new products.

Contributors JE led data analysis, acquisition, and led writing of the paper. PML obtained funding, supervised, and contributed to analysis and critical revision of the paper. Both authors approved the final manuscript for submission. Both authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This work was supported by the National Cancer Institute, National Institutes of Health (Grant R01-87472).

Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All documents are publicly available at https://www.industrydocuments.library.ucsf.edu.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1 Proctor RN. Golden Holocaust: Origins of the Cigarette Catastrophe and the Case for Abolition, 2012. UC Press;
2 Bemidge V. Electronic cigarettes and history. The Lancet 2014;383:2204–5.
3 Anderson SJ, Ling PM. “And they told two friends… and so on”: RJ Reynolds’ viral marketing of Eclipse and its potential to mislead the public. Tob Control 2008;17:222–9.
4 Parascandola M, Augustson E, O’Connell ME, et al. Consumer awareness and attitudes related to new potential reduced-exposure tobacco product brands. Nicotine Tob Res 2009;11:886–95.
5 R.R. Premier Objectives: RJ Reynolds Records, 1988. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/fmmk0848.
6 Kampe R. Importance of Premier: RJ Reynolds Records, 1987. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/hbj0098.
7 The Lancet. Nicotine use after the year 2000. Lancet 1991;337:1191–2.
8 Yach D. Foundation for a smoke-free world. The Lancet 2017;390:1807–10.
9 Malone RE, Balbach ED. Tobacco industry documents: treasure trove or quagmire? Tob Control 2000;9:14–19.
10 Balbach ED, Gasior RJ, Barbeau EM. Tobacco industry documents: comparing the tobacco industry documents: treasure trove or quagmire? Tob Control 2000;9:14–19.
11 Carter SM. Tobacco document research reporting. Tob Control 2005;14:368–76.
12 Elam M, Gunnarsson A. The advanced liberal logic of nicotine replacement and the Swedish invention of smoking as addition. Transformations of the Swedish welfare state. Springer; 2012:137–52.
13 R.R. Premier Marketing Plan: RJ Reynolds Records, 1987. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/rdtq0095.
14 Fischer PW. Tactical Plans for Premier: RJ Reynolds Records, 1987. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/rivy0098.
15 deBethizy JD, Borgerding MF, Doolittle Dl, et al. Chemical and biological studies of a cigarette that heats rather than burns tobacco. J Clin Pharmacol 1990;30:755–63.
16 deBethizy JD, Foulke LS. Letter to Lancer: RJ Reynolds, 1990. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/mwso0082.
17 Burger GT. Weekly Toxicology Highlights: RJ Reynolds, 1989. https://industrydocuments.library.ucsf.edu/tobacco/docs/ddrdm0092.
18 deBethizy JD. Submission Letter to New England Journal of Medicine: RJ Reynolds, 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/wmvo0095.
19 deBethizy JD. Submission Letter to Lancet: RJ Reynolds, 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/kmgo0079.
20 deBethizy JD. Memo Re: Lancet Submission: RJ Reynolds, 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/jmgo0079.
21 Sharp D. Rejection Letter from Lancer: RJ Reynolds; Billey, 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xgpb0024.
22 Elias J, Ling PM. Origins of tobacco harm reduction in the UK: the ‘Product Modification Programme’ (1992–1991). Tob Control 2018;27:1(e1):e12–e18.
23 Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. Br Med J 1976;1:1423–3.
24 Hajek P. The development and testing of new nicotine replacement treatments: from ‘nicotine replacement’ to ‘smoking replacement’. Addiction 2015;11 Suppl 2(S2):19–22.
25 Royal College of Physicians. Helping People who Can’t Quit. Royal College of Physicians of London, 2007. Report No: 186016319X.
26 ASH. ASH endorses RCP call for a tobacco harm reduction strategy. London: Action on Smoking and Health, 2007.
27 Public Health England. E-cigarettes: A new foundation for evidence-based policy and practice. London: Public Health England, 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/454517/E-cigarettes_a_firm__foundation_for_evidence_based_policy_and_practice.pdf.
28 Royal College of Physicians. Nicotine Without Smoke: Tobacco Harm Reduction. London: Royal College of Physicians, 2016.
29 Medicines and Healthcare Products Regulatory Agency. MHRA Public Assessment Report: The use of nicotine replacement therapy to reduce harm in smokers. London, 2010. http://webarchive.nationalarchives.gov.uk/20141205150103/http://www.mhra. gov.uk/home/groups/es-policy/documents/publication/crr06851.pdf.
30 UK National Health Service. E-cigarettes. 2018. https://www.nhs.uk/smokefree/help-and-advice/e-cigarettes.
31 Elam M. Pharmaceutical incursion on cigarette smoking at the birth of the brain disease model of addiction: Advances in Medical Sociology, 2012.
32 Thornton RE. Note on Collaborative Study with Russell: British American Tobacco, 1979. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xwvo0211.
33 Russell M. Russell’s Proposal for Joint Study with BAT: British American Tobacco, 1979. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/mjko0207.
34 Thornton RE. BAT Approves Russell’s Funding for Joint Study: British American Tobacco, 1980. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/mjkg0207.
35 Russell M. Russell Thanks BAT for Financial Support: British American Tobacco, 1980. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xnmo0203.
36 Short PL. Funding Proposal for Michael Russell: British American Tobacco, 1979. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xjvo0211.
37 Russell M. Conversation with Michael AH Russell: Addiction (Abingdon, England, 2004:99:9–19.
38 Russell M. Letter from Russell to Thornton re: Premier: British American Tobacco Records, 1993. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/hsy0203.
39 Lloyd RA. Russell’s Premier Study Described: RJ Reynolds, 1988. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/dhpd0030.
40 Russell M. Russell Discusses Clearing Premier Cigarettes at Customs: RJ Reynolds, 1988. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xzvo0090.
41 Blanchard JW. R.R discusses Russell’s Research Proposal: RJ Reynolds, 1988. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xhyl0087.
42 Russell M. Letter to A. Wallace Hayes: RJ Reynolds, 1991. https://industrydocuments.library.ucsf.edu/tobacco/docs/msvo0084.
43 Sunderland G, Russell MA, Stapleton JA, et al. Glycerol particle cigarettes: a less harmful option for chronic smokers. Thorax 1993;48:385–7.
44 Russell MA. The future of nicotine replacement. Br J Addict 1991;86:653–8.
45 Marcutoli RJ. ISCMW slows things down with Premier: RJ Reynolds, 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/rhvb0001.
46 deBethizy JD. Interoffice Memo re: Lancet Editorial on Nicotine: RJ Reynolds, 1991. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/mjng0029.
47 deBethizy JD. 1992-1996 Strategic Plan: RJ Reynolds. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/fmmw0103.
48 Russell M. Letter re: Premier cigarettes: Depositions and Trial Testimony (DATTA), 1993. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/qtko0154.
49 Emmann C. Letter to Russell re: Premier’s future: RJ Reynolds Records, 1993. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/xqwo0089.
50 Morris PM. International Harm Reduction Equation. 2017. https://www.pmi.com/glossary-section/glossary/harm-reduction-equation.
51 Elia J, Hendlin YH, Ling PM. Public versus internal conceptions of addiction: An analysis of internal Philip Morris documents. PLoS Med 2018;15:e1002562.
52 Philip Morris International. Science and Innovation: The Role of Nicotine. 2017 https://www.pmi.com/science-and-innovation/the-role-of-nicotine (accessed 20 Sep 2017).
53 LeGresley EM, Murphy MI. UKAD. Playing hide-and-seek with the tobacco industry, Nicotine Tob Res 2005;7:27–40.
54 Kulik MC, Glantz SA. The smoking population in the USA and EU is softening not hardening. Tob Control 2016;25:470–5.
55 Peeters S, Gilmore AB. Understanding the emergence of the tobacco industry’s use of the term tobacco harm reduction in order to inform public health policy. Tob Control 2015;24:182–9.
56 Kaplan J. Philip Morris Plunges the Most in a Decade on Slump in Cigarettes, 2016. (9 May 2018).
57 Philip Morris International. Designing a Smoke-Free Future. 2017 https://www.pmi.com/who-we-are/designing-a-smoke-free-future (accessed 13 Feb 2017).
58 Foundation For a Smoke-Free World. Global Foundation Launches to Accelerate an End to Smoking, 2017 https://www.smokefreeworld.org/newsroom/global-foundation-launches-accelerate-end-smoking.
59 Sun L. Philip Morris International Proves That “Heated” Cigarettes Can Sell. The Motely Fool 2016.
60 Kaplan J. Philip Morris Plunges the Most in a Decade on Slump in Cigarettes. 2018 https://www.bloomberg.com/news/articles/2018-04-19/philip-morris-sales-disappoint-as-cigarette-demand-slips-further.
61 Malone RE, Chapman S, Gupta PC, et al. A “Frank Statement” for the 21st Century? In: BMJ Publishing Group Ltd 2017.
62 Daube M, Moodie R, McKee M. Towards a smoke-free world? Philip Morris International’s new Foundation is not credible. Lancet 2017;390:1722–4.
63 Slade J, Connolly GN, Lymperis D. Eclipse: does it live up to its health claims? Tob Control 2002;11 Suppl 2:64–70.
64 US v. Philip Morris Inc. In: F. Supp. 2d: Dist. Court, Dist. of Columbia. 2000.
65 The Lancet. About Us - The Best Science for Better Lives. 2017 http://www.thelancet.com/about-us (accessed 4 Oct 2017).
66 Hendlin YH, Elias J, Ling PM. The Pharmaceuticalization of the Tobacco Industry. Ann Intern Med 2017;167:278–80.
67 National Academies of Sciences. Public Health Consequences of E-Cigarettes. Washington D.C. 2018. https://www.nap.edu/catalog/24952/public-health-consequences-of-e-cigarettes.
68 Malone RE, Bialous SA. WHO FCTC article 5.3: promise but little progress. Tob Control 2014;23:279–80.
69 Parascandola M. Lessons from the history of tobacco harm reduction: The National Cancer Institute’s Smoking and Health Program and the “less hazardous cigarette”. Nicotine Tob Res 2005;7:779–89.
70 Slade J, Connolly GN, Lymperis D. Eclipse: does it live up to its health claims? Tob Control 2002;11 Suppl 2:64–70.
71 Cline ML. Notes re: Premier Paper: RJ Reynolds, 1989. https://industrydocuments.library.ucsf.edu/tobacco/docs/nlgw0079.
72 Hayes A.W. Hayes sends Russell copy of deBethizy Manuscript: RJ Reynolds., 1989. https://www.industrydocuments.library.ucsf.edu/tobacco/docs/qrxd0079.
73 DeBethizy JD. Submission Letter to the Journal of Clinical Pharmacology: RJ Reynolds, 1990. https://industrydocuments.library.ucsf.edu/tobacco/docs/mqkg0084.
74 Steele R. Spa Highlights: September 19-23: RJ Reynolds, 1988. https://industrydocuments.library.ucsf.edu/tobacco/docs/rnjd0003.